Evidence map›Paper›PMID 38888822›Full record

ReviewCurrent hematologic malignancy reports2024

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.

Valerie Tran, Kiarash Salafian, Kenan Michaels, Caroline Jones, Daniel Reed, Michael Keng, Firas El Chaer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Valerie TranDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA.
Kiarash SalafianDepartment of Medicine, The University of Virginia, Charlottesville, VA, USA.
Kenan MichaelsDepartment of Medicine, The University of Virginia, Charlottesville, VA, USA.
Caroline JonesDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA.
Daniel ReedDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA.
Michael KengDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA.
Firas El ChaerDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, USA. fe2gh@uvahealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewMeasurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice. RECENT

findingsNew molecular technologies have allowed the detection of MRD to levels as low as 10

Indexed as

Neoplasm, ResidualPhiladelphia ChromosomePrecursor Cell Lymphoblastic Leukemia-LymphomaHematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHumansAcute Lymphoblastic LeukemiaBlinatumomabInotuzumab OzogamicinMeasurable Residual DiseasePhiladelphia PositiveTisagenlecleucel

Identifiers

PMID38888822
PMCPMC11316691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.